Why natural killer cells in triple negative breast cancer?

doi:10.5306/wjco.v11.i7.464

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12550)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

741

WORD

189

HTML

6725

Figures (1-4)

841

Tables (1-1)

650

Sum=9146

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

440

Download

1014

Sum=1454

Publishing Process of This Article

Item

Count

Browse

706

Download

1244

Sum=1950

Jul 24, 2020 (publication date) through Oct 31, 2025

Times Cited of This Article

Times Cited (45)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Clin Oncol. Jul 24, 2020; 11(7): 464-476
Published online Jul 24, 2020. doi: 10.5306/wjco.v11.i7.464

Table 1 List of immunotherapeutic agents in various clinical trial phases and earliest expected completion dates of most significant trials[20]

Drug	Function	Trial phase	Est. date of completion
Pembrolizumab	PD-1 Inhibitor	III	December 2019
Nivolumab	PD-1 Inhibitor	II	August 2022
Atezolizumab	PDL-1 Inhibitor	III	April 2020
Avelumab	PDL-1 Inhibitor	III	June 2023
Durvalumab	PD-1 Inhibitor	I/II	October 2019
Tremelimumab	CTLA-4 Inhibitor	II	October 2018¹

¹Phase II complete, phase III not yet begun. PD: Programmed death; PDL: Programmed death ligand; CTLA-4: Cytotoxic T-lymphocyte-associated protein 4.

Full Size Table

Citation: Abdel-Latif M, Youness RA. Why natural killer cells in triple negative breast cancer? World J Clin Oncol 2020; 11(7): 464-476
URL: https://www.wjgnet.com/2218-4333/full/v11/i7/464.htm
DOI: https://dx.doi.org/10.5306/wjco.v11.i7.464